Literature DB >> 12942373

Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome.

Carl Grunfeld1, Phyllis Tien.   

Abstract

With the introduction of combination antiretroviral therapy, changes in fat distribution and serum metabolites were reported. These included increased central fat ("buffalo hump," abdominal, and visceral); decreased peripheral fat (in the face, legs, and arms); increased levels of triglycerides, low-density lipoprotein and total cholesterol, glucose, and insulin; and low levels of high-density lipoprotein cholesterol. Many of these changes predict increased atherosclerosis. It has been proposed that these findings are part of a single syndrome, much like metabolic syndrome. Our data indicate that many of these changes are independent. Some changes are antiretroviral drug (but not necessarily class)-specific, some represent the restoration to health, and others are due to effects of the host response to human immunodeficiency virus itself.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12942373     DOI: 10.1086/375886

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

Review 1.  The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications.

Authors:  Mustafa A Noor
Journal:  Curr HIV/AIDS Rep       Date:  2007-08       Impact factor: 5.071

2.  Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals.

Authors:  Supriya Krishnan; Jeffrey T Schouten; Benjamin Atkinson; Todd Brown; David Wohl; Grace A McComsey; Marshall J Glesby; Cecilia Shikuma; Richard Haubrich; Pablo Tebas; Thomas B Campbell; Denise L Jacobson
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

3.  Leptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications.

Authors:  Sotirios Tsiodras; Christos Mantzoros
Journal:  Am J Infect Dis       Date:  2006

4.  High prevalence of lipid abnormalities among antiretroviral-naive HIV-infected Asian children with mild-to-moderate immunosuppression.

Authors:  Suparat Kanjanavanit; Thanyawee Puthanakit; Ung Vibol; Pope Kosalaraksa; Rawiwan Hansudewechakul; Chaiwat Ngampiyasakul; Jurai Wongsawat; Wicharn Luesomboon; Jiratchaya Wongsabut; Apicha Mahanontharit; Tulathip Suwanlerk; Vonthanak Saphonn; Jintanat Ananworanich; Kiat Ruxrungtham
Journal:  Antivir Ther       Date:  2011

Review 5.  The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications.

Authors:  Oliver P Flint; Mustafa A Noor; Paul W Hruz; Phil B Hylemon; Kevin Yarasheski; Donald P Kotler; Rex A Parker; Aouatef Bellamine
Journal:  Toxicol Pathol       Date:  2009-01-26       Impact factor: 1.902

6.  The role of HIV and monocytes/macrophages in adipose tissue biology.

Authors:  Cecilia M Shikuma; Louie Mar A Gangcuangco; Deirdre A Killebrew; Daniel E Libutti; Dominic C Chow; Beau K Nakamoto; Chin Yuan Liang; Cris I P Milne; Lishomwa C Ndhlovu; Jason D Barbour; Bruce T Shiramizu; Mariana Gerschenson
Journal:  J Acquir Immune Defic Syndr       Date:  2014-02-01       Impact factor: 3.731

7.  The association between diet and physical activity on insulin resistance in the Women's Interagency HIV Study.

Authors:  Nancy A Hessol; Niloufar Ameli; Mardge H Cohen; Sally Urwin; Kathleen M Weber; Phyllis C Tien
Journal:  J Acquir Immune Defic Syndr       Date:  2013-01-01       Impact factor: 3.731

Review 8.  Hormonal contraception and HIV-positive women: metabolic concerns and management strategies.

Authors:  Julie Womack; Susan Richman; Phyllis C Tien; Margaret Grey; Ann Williams
Journal:  J Midwifery Womens Health       Date:  2008 Jul-Aug       Impact factor: 2.388

9.  Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection.

Authors:  Richard K Sterling; Melissa J Contos; Paula G Smith; R Todd Stravitz; Velimir A Luketic; Michael Fuchs; Mitchell L Shiffman; Arun J Sanyal
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

10.  Lack of an Effect of Ritonavir Alone and Lopinavir-Ritonavir on the Pharmacokinetics of Fenofibric Acid in Healthy Volunteers.

Authors:  Lori A Gordon; Christine Y Malati; Colleen Hadigan; Mary McLaughlin; Raul M Alfaro; Mónica M Calderón; Joseph A Kovacs; Scott R Penzak
Journal:  Pharmacotherapy       Date:  2016-01       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.